Clinical Trials | December 12, 2025
Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The new centre brings advanced corneal procedures pioneered in India
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
While Merck can appeal, Halozyme said it expects the order to hold
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Growing patent filings and tier-2 innovators reflect expanding national research base
The company is excluding data from the affected sites to maintain the study's integrity
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Subscribe To Our Newsletter & Stay Updated
